Temodar — CareFirst (Caremark)
Mycosis fungoides (MF)
Initial criteria
- Authorization may be granted for treatment of MF or SS as single agent subsequent therapy for CNS involvement.
Reauthorization criteria
- Authorization may be renewed if there is no evidence of unacceptable toxicity or disease progression while on the current regimen.
Approval duration
12 months